Squarepoint’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

Squarepoint’s Portfolio PRDS Stock Details PRDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-12,211	Closed	-$22.1K	–	4387
2023 Q2	$22.1K	Buy	+12,211	New	+$22.3K	﹤0.01%	3487
2022 Q2	–	Sell	-22,832	Closed	-$165K	–	3560
2022 Q1	$165K	Buy	+22,832	New	+$225K	﹤0.01%	2522

Other funds holding PRDS

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Squarepoint's PRDS Position: Q3 2023 in Review

Squarepoint sold out of Pardes Biosciences, Inc. Common Stock (PRDS) in Q3 2023, closing a stake of 12,211 shares — an estimated $22.1K sold.

Squarepoint first reported a position in PRDS in Q1 2022 and held it in 2 quarters. The position peaked at $165K in Q1 2022. 1 fund tracked by Wall St. Rank holds PRDS as of Q3 2023.

Squarepoint reported no remaining Pardes Biosciences, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Squarepoint sold 12,211 Pardes Biosciences, Inc. Common Stock shares in Q3 2023, an estimated $22.1K.
Squarepoint first reported a position in Pardes Biosciences, Inc. Common Stock in Q1 2022 and held it in 2 quarters.
Squarepoint's Pardes Biosciences, Inc. Common Stock position peaked at $165K in Q1 2022.
1 fund tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q3 2023.

Based on Squarepoint's 13F filing for Q3 2023, filed 14 Nov 2023.